ZA201700488B - Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same - Google Patents
Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for sameInfo
- Publication number
- ZA201700488B ZA201700488B ZA2017/00488A ZA201700488A ZA201700488B ZA 201700488 B ZA201700488 B ZA 201700488B ZA 2017/00488 A ZA2017/00488 A ZA 2017/00488A ZA 201700488 A ZA201700488 A ZA 201700488A ZA 201700488 B ZA201700488 B ZA 201700488B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibody
- cytoplasm
- positioning
- same
- cell membrane
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 210000000170 cell membrane Anatomy 0.000 title 1
- 210000000805 cytoplasm Anatomy 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 230000000149 penetrating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140092673 | 2014-07-22 | ||
| KR1020150103163A KR101602870B1 (ko) | 2014-07-22 | 2015-07-21 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| PCT/KR2015/007626 WO2016013870A1 (ko) | 2014-07-22 | 2015-07-22 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201700488B true ZA201700488B (en) | 2018-12-19 |
Family
ID=55354088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/00488A ZA201700488B (en) | 2014-07-22 | 2017-01-20 | Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10844136B2 (enExample) |
| EP (1) | EP3173428B1 (enExample) |
| JP (1) | JP6595592B2 (enExample) |
| KR (1) | KR101602870B1 (enExample) |
| CN (1) | CN107001481A (enExample) |
| AU (1) | AU2015292955B2 (enExample) |
| BR (1) | BR112017001304A2 (enExample) |
| CA (1) | CA2955272A1 (enExample) |
| IL (1) | IL250203B (enExample) |
| RU (1) | RU2017103675A (enExample) |
| ZA (1) | ZA201700488B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012135831A1 (en) | 2011-04-01 | 2012-10-04 | Yale University | Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair |
| KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| KR102000000B1 (ko) * | 2016-05-27 | 2019-07-12 | 오름테라퓨틱 주식회사 | 항체에 엔도좀 탈출능을 부여하는 엔도좀 탈출 구조 모티프 및 이의 활용 |
| JP2019520086A (ja) | 2016-05-27 | 2019-07-18 | オラム・セラピューティクス・インコーポレイテッド | 細胞質浸透抗体およびその用途 |
| WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| WO2017218825A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| WO2019107812A1 (ko) | 2017-11-16 | 2019-06-06 | 오름테라퓨틱 주식회사 | 세포의 세포질에 침투하여 세포내 활성화된 ras를 억제하는 항체 및 이의 용도 |
| US12304970B2 (en) | 2018-02-01 | 2025-05-20 | Yale University | Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus |
| CN112218621A (zh) * | 2018-04-10 | 2021-01-12 | 西北大学 | 包含基于靶向亲和域的膜蛋白的胞外囊泡 |
| US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
| JP2021532135A (ja) * | 2018-07-23 | 2021-11-25 | 中外製薬株式会社 | 標的細胞特異的な細胞質侵入抗原結合分子 |
| CN110759996B (zh) * | 2018-07-27 | 2022-09-06 | 深圳康体生命科技有限公司 | 一种gfp抗体 |
| CN108949565B (zh) * | 2018-09-26 | 2024-09-06 | 中国科学技术大学 | 用于红细胞负载冻干保护剂的装置及方法 |
| CN113825515A (zh) * | 2019-05-01 | 2021-12-21 | 圣地亚哥德孔波斯特拉大学 | 调配成纳米胶囊的抗kras抗体的胞内递送 |
| US20230076637A1 (en) | 2020-02-06 | 2023-03-09 | Ajou University Industry-Academic Cooperation Foundation | Fusion antibody for presenting antigen-derived t cell antigen epitope or peptide containing same on cell surface, and composition comprising same |
| WO2021170684A1 (en) * | 2020-02-24 | 2021-09-02 | Oblique Therapeutics Ab | Kras epitopes and antibodies |
| PE20231504A1 (es) * | 2020-04-30 | 2023-09-26 | Genentech Inc | Anticuerpos especificos para kras y sus usos |
| KR102623211B1 (ko) | 2021-07-20 | 2024-01-11 | 아주대학교산학협력단 | 세포 내부에 침투하여 표적단백질을 분해하여 제거하는 세포침투 분해항체 및 이의 용도 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2706486B1 (fr) | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| CN1241574A (zh) * | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体 |
| GB0226727D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| AU2003219277A1 (en) | 2002-03-14 | 2003-09-29 | Medical Research Council | Intracellular antibodies |
| CA2506128A1 (en) | 2002-11-15 | 2004-06-03 | Medical Research Council | Anti-activated ras antibodies |
| BRPI0709340A2 (pt) | 2006-03-27 | 2013-04-16 | Globeimmune Inc | mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma |
| US20110189206A1 (en) | 2008-01-03 | 2011-08-04 | Barbas Iii Carlos F | Antibody Targeting Through a Modular Recognition Domain |
| KR100849941B1 (ko) * | 2008-04-29 | 2008-08-01 | 원우이에프엔지니어링주식회사 | 열 및 연기 화재감지장치 복합시험기 |
| JP2011519370A (ja) * | 2008-04-30 | 2011-07-07 | アジョウ・ユニヴァーシティ・インダストリー−アカデミック・コーオペレーション・ファンデーション | 癌細胞の細胞死を誘導する抗核酸抗体及びこれを用いた癌予防または治療用組成物 |
| KR101075123B1 (ko) * | 2008-10-24 | 2011-10-19 | 아주대학교산학협력단 | 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도 |
| WO2010056043A2 (en) * | 2008-11-11 | 2010-05-20 | Ajou University Industry-Academic Cooperation Foundation | Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same |
| CN101402675B (zh) | 2008-11-28 | 2012-05-30 | 中国人民解放军第三军医大学第三附属医院 | 一种靶向抑制ανβ3阳性细胞增殖的环肽 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| GB201103631D0 (en) | 2011-03-03 | 2011-04-13 | Univ Leeds | Identification of candidate therapeutics |
| WO2012135831A1 (en) | 2011-04-01 | 2012-10-04 | Yale University | Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair |
| US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US9815866B2 (en) | 2012-09-14 | 2017-11-14 | Japanese Foundation For Cancer Research | Peptides that bind to epithelial cell adhesion molecule |
| WO2015048477A1 (en) | 2013-09-27 | 2015-04-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| WO2016013871A1 (ko) | 2014-07-22 | 2016-01-28 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| US20180208658A1 (en) | 2015-04-03 | 2018-07-26 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
| KR101790669B1 (ko) | 2015-10-14 | 2017-10-26 | 아주대학교산학협력단 | 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도 |
| JP2019520086A (ja) | 2016-05-27 | 2019-07-18 | オラム・セラピューティクス・インコーポレイテッド | 細胞質浸透抗体およびその用途 |
| KR101836392B1 (ko) | 2016-08-17 | 2018-03-08 | 한림대학교 산학협력단 | 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물 |
| WO2019107812A1 (ko) | 2017-11-16 | 2019-06-06 | 오름테라퓨틱 주식회사 | 세포의 세포질에 침투하여 세포내 활성화된 ras를 억제하는 항체 및 이의 용도 |
| US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
-
2015
- 2015-07-21 KR KR1020150103163A patent/KR101602870B1/ko active Active
- 2015-07-22 EP EP15825418.5A patent/EP3173428B1/en active Active
- 2015-07-22 RU RU2017103675A patent/RU2017103675A/ru not_active Application Discontinuation
- 2015-07-22 US US15/327,369 patent/US10844136B2/en not_active Expired - Fee Related
- 2015-07-22 JP JP2017525495A patent/JP6595592B2/ja not_active Expired - Fee Related
- 2015-07-22 BR BR112017001304-5A patent/BR112017001304A2/pt not_active Application Discontinuation
- 2015-07-22 CN CN201580045139.0A patent/CN107001481A/zh active Pending
- 2015-07-22 AU AU2015292955A patent/AU2015292955B2/en not_active Ceased
- 2015-07-22 CA CA2955272A patent/CA2955272A1/en not_active Abandoned
-
2017
- 2017-01-19 IL IL250203A patent/IL250203B/en not_active IP Right Cessation
- 2017-01-20 ZA ZA2017/00488A patent/ZA201700488B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3173428A4 (en) | 2018-01-24 |
| EP3173428B1 (en) | 2020-02-19 |
| CN107001481A (zh) | 2017-08-01 |
| US10844136B2 (en) | 2020-11-24 |
| AU2015292955A1 (en) | 2017-02-09 |
| US20170218084A1 (en) | 2017-08-03 |
| KR20160011598A (ko) | 2016-02-01 |
| KR101602870B1 (ko) | 2016-03-21 |
| JP6595592B2 (ja) | 2019-10-23 |
| IL250203A0 (en) | 2017-03-30 |
| CA2955272A1 (en) | 2016-01-28 |
| AU2015292955B2 (en) | 2020-08-13 |
| BR112017001304A2 (pt) | 2018-01-30 |
| RU2017103675A (ru) | 2018-08-06 |
| EP3173428A1 (en) | 2017-05-31 |
| JP2017529097A (ja) | 2017-10-05 |
| IL250203B (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201700488B (en) | Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same | |
| IL320713A (en) | Antibodies, uses and methods | |
| DK3174874T3 (da) | Berberinsalte, ursodeoxycholsalte og kombinationer, fremgangsmåder til fremstilling og anvendelse deraf. | |
| ZA202105220B (en) | Cell penetrating antibodies | |
| SG11201706826VA (en) | Method for separating cells, and device therefor | |
| EP3130604A4 (en) | Anti-il-17 antibodies, method for producing same and method for using same | |
| EP3150692A4 (en) | Cell evaluation device, method, and program | |
| EP3173099A4 (en) | Method for suppressing ras activated in cell by using antibody having cytoplasm penetration capacity and complete immunoglobulin form, and use for same | |
| EP3150693A4 (en) | Cell determination device, method, and program | |
| EP3091786A4 (en) | Apparatus, method and system for cell selection | |
| EP3133865A4 (en) | Method, device and system for cell reselection | |
| EP3176277A4 (en) | Ferritic stainless steel material for fuel cell, and method for producing same | |
| EP3239691A4 (en) | Cell imaging device, cell imaging method, and sample cell | |
| EP3118750A4 (en) | Factor analysis device, factor analysis method, and factor analysis program | |
| IL252430A0 (en) | Antibodies, uses and methods | |
| SG11201701562WA (en) | Cell trapping method, method for producing specific cell-trapping device, and method for producing specific cell-containing solution | |
| EP3150694A4 (en) | Cell evaluation device, method, and program | |
| EP3107141A4 (en) | Microbial fuel cell, microbial fuel cell system, and method for using microbial fuel cell | |
| EP3226607A4 (en) | Method and apparatus for transmitting information in cell | |
| KR101687291B9 (ko) | 3차원 세포배양 시스템 및 이를 이용한 세포 배양 방법 | |
| BR112016030851A2 (pt) | recipiente de separação de células, sistema de separação de células e método de separação de células | |
| EP3275993B8 (en) | Device for producing information for cell analysis, method for producing information for cell analysis, and program | |
| SG11201700557RA (en) | Lipid membrane structure, lipid-membrane-structure-immobilization carrier, and method for fusing cells | |
| HUE051941T2 (hu) | Biológiai élesztõ, eljárás elõállítására és alkalmazásai | |
| HK40042519B (zh) | 抗体、用途和方法 |